- Home
- ANIX vs STRO Comparison
ANIX vs STRO Comparison
Compare ANIX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | STRO |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 85.0M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | STRO |
|---|---|---|
| Price | $2.82 | $21.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | $9.00 | ★ $18.50 |
| AVG Volume (30 Days) | 82.4K | ★ 126.5K |
| Earning Date | 03-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $0.52 |
| 52 Week High | $5.46 | $27.96 |
Technical Indicators
Market Signals| Indicator | ANIX | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 49.98 |
| Support Level | N/A | $0.76 |
| Resistance Level | $3.10 | $27.96 |
| Average True Range (ATR) | 0.17 | 2.14 |
| MACD | -0.01 | -0.58 |
| Stochastic Oscillator | 10.00 | 22.55 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.